A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Abstract

The interaction between immune checkpoint inhibitors (ICIs) and radiotherapy has significantly improved the treatment outcomes for patients with cancer. ICIs activate the immune system by blocking the programmed death-1 (PD-1), programmed cell death-Ligand 1(PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling pathways, thereby killing tumor cells. Radiotherapy activates local and abscopal effects by killing tumor cells, inducing immunogenic death, and releasing antigens and damage-related molecules. The combination of the two methods forms a closed-loop process of “antigen release-immune activation,” which significantly improves the therapeutic effect of patients with cancer. Clinical studies have shown that ICIs combined with radiotherapy can significantly improve the objective response rate (ORR) and progression-free survival (PFS) in patients with solid tumors, such as Non-Small Cell Lung Cancer (NSCLC) and melanoma. However, heterogeneous responses, immune-related adverse events (irAEs), and drug resistance are still common clinical problems. Optimizing the fractionation of radiotherapy dose, timing of synchronous intervention, and biomarkers, such as tumor mutation burden, are key to improving tumor treatment efficacy. In the future, precise tumor treatment is expected to improve patient prognosis through the interaction between ICIs and radiotherapy.

Keywords

Clinical application / ICIs / Radiotherapy / Synergistic mechanism

References

[1] Mudra SE, Rayes DL, Agrawal A, et al. Immune checkpoint inhibitors and pericardial disease: a systematic review. Cardiooncology. 2024; 10(1): 29.

[2] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16): 1535-1546.

[3] Li Q, Cai YQ, Shao LH, et al. Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review). Oncol Lett. 2025; 30(4): 469.

[4] Monjazeb AM, Schalper KA, Villarroel-Espindola F, et al. Effects of Radiation on the Tumor Microenvironment. Semin Radiat Oncol. 2020; 30(2): 145-157.

[5] Kreileder M, Barrett I, Bendtsen C, et al. Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints. Trends Cell Biol. 2021; 31(3): 224-235.

[6] Wang H, Yao Z, Kang K, et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024; 5(10): 1237-1254.

[7] Zhang Y, Li J, Guo X, et al. Tumor-Specific MHC-II Activates CD4+ and CD8+ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy. Cancer Res. 2025; 85(17): 3258-3274.

[8] Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3): 200-218.

[9] Wang Q, Shao X, Zhang Y, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023; 12(10): 11149-11165.

[10] Tjader NP, Toland AE. Immunotherapy for colorectal cancer: insight from inherited genetics. Trends Cancer. 2024; 10(5): 444-456.

[11] Li C, Jiang P, Wei S, et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020; 19(1): 116.

[12] Jiang Y, Dai A, Huang Y, et al. Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell. 2025; 188(9): 2354-2371.e18.

[13] Gomes de Morais AL, Cerdá S, de Miguel M. New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. Curr Oncol Rep. 2022; 24(5): 651-658.

[14] Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022; 10(4):e004711.

[15] Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020; 20(3): 173-185.

[16] Zhai D, An D, Wan C, et al. Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol. 2022; 19:101366.

[17] Xue H, Chen Y, Zhou Y. Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer. Front Immunol. 2024; 15:1522508.

[18] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1): 1-10.

[19] Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024; 57(4): 752-771.

[20] Yin X, Ding Z, Yu L, et al. Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice. Nat Commun. 2025; 16(1): 6020.

[21] Ma W, Luo H, Lv J, et al. Immunoregulatory Engineering of Semiconducting Charge-Reversal Nanoantioxidant for Ameliorating Cancer Radioimmunotheranostics. Adv Mater. 2024; 36(31):e2402929.

[22] Nelson BE, Adashek JJ, Lin SH, et al. The abscopal effect in patients with cancer receiving immunotherapy. Med. 2023; 4(4): 233-244.

[23] Meng K, Lu H. Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors. Prec Radiat Oncol. 2024; 8: 42–46.

[24] Yang Y, Wu M, Cao D, et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv. 2021; 7(41):eabf6290.

[25] Chen H, Li Y, Shen Q, et al. Reduced irradiation exposure areas enhanced anti-tumor effect by inducing DNA damage and preserving lymphocytes. Mol Med. 2024; 30(1): 284.

[26] Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022; 10:20503121211069012.

[27] Chen Y, Gao M, Huang Z, et al. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 2020; 13(1): 105.

[28] O'Donoghue J, Zanzonico P, Humm J, et al. Dosimetry in Radiopharmaceutical Therapy. J Nucl Med. 2022; 63(10): 1467-1474.

[29] Lotem M, Merims S, Frank S, et al. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma]. Harefuah. 2012; 151(10): 585-588,

[30] Newell F, Pires da Silva I, Johansson PA, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell. 2025; 43(3): 563.

[31] Wei J, Montalvo-Ortiz W, Yu L, et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol. 2021; 6(58):eabg0117.

[32] Cytryn SL, Moy RH, Cowzer D, et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023; 24(10): 1073-1082.

[33] Spigel DR, Faivre-Finn C, Gray JE, et al.Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12): 1301-1311.

[34] Sagus S, Sawsan R, Puneeth I, et al.Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 triale. Clin Med. 2025; 87:103435.

[35] Zhou F, Guo H, Xia Y, et al.The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025; 22(2): 95-116.

[36] Pierini S, Mishra A, Perales-Linares R, et al.Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. J Immunother Cancer. 2021; 9(2):e001636.

[37] Boopathi E, Den RB, Thangavel C. Innate Immune System in the Context of Radiation Therapy for Cancer. Cancers (Basel). 2023; 15(15): 3972.

[38] Chiang SF, Huang CY, Ke TW, et al.Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother. 2019; 68(2): 283-296.

[39] Chiang CL, Chiu KWH, Chan KSK, et al.Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023; 8(2): 169-178.

[40] Guo S, Yao Y, Tang Y, et al.Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023; 8(1): 205.

[41] Salama AKS, Palta M, Rushing CN, et al.Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clin Cancer Res. 2021; 27(5): 1287-1295.

[42] Puza CJ, Bressler ES, Terando AM, et al. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. J Surg Res. 2019; 236: 209-215.

[43] Damen PJJ, Suijkerbuijk KPM, VAN Lindert ASR, et al. Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors. Anticancer Res. 2022; 42(10): 4795-4804.

[44] Mahmood U, Huynh MA, Killoran JH, et al. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2022; 114(4): 666-675.

[45] Shiao S, Gouin K, Ing N, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024; 42(1): 70-84.

[46] Shen Y, Connolly E, Aiello M, et al. Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nat Commun. 2025; 16(1): 3522.

[47] Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021; 17(10): 1143-1153.

[48] Che G, Yin J, Wang W, et al. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resist Updat. 2024; 74:101080.

[49] Miao K, Zhang L. Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects. Chin Med J Pulm Crit Care Med. 2023; 1(4): 215-222.

[50] Goligher EC, Lawler PR, Jensen TP, et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA. 2023; 329(13): 1066-1077.

[51] Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025; 25(5): 353-369.

[52] Goyal A, Bauer J, Hey J, et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023; 14(1): 6731.

[53] Lussier DM, Alspach E, Ward JP, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A. 2021; 118(24):e2102611118.

[54] Czekay RP, Cheon DJ, Samarakoon R, et al. Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets. Cancers (Basel). 2022; 14(5): 1231.

[55] Han H, He T, Wu Y, et al. Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms. Front Cell Dev Biol. 2024; 12:1441081.

[56] Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol. 2021; 18(4): 866-877.

[57] Mortaja M, Adams SR, McKay RR, et al. Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies. NPJ Precis Oncol. 2025; 9(1): 97.

[58] Bratus AS, Bocharov G, Grebennikov D. Dynamic Programming-Based Approach to Model Antigen-Driven Immune Repertoire Synthesis. Mathematics. 2024; 12(20): 3291

Rights & permissions

2026 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.